Éric Tartour

Active 1994–2025

Also published as
Eric Tartour
122
Papers
21,912
Citations
82
h-index
117
i10-index

Citations

Citations per year for Éric Tartour1995: 1 citations1996: 5 citations1997: 5 citations1998: 19 citations1999: 15 citations2000: 15 citations2001: 28 citations2002: 28 citations2003: 21 citations2004: 25 citations2005: 22 citations2006: 26 citations2007: 43 citations2008: 46 citations2009: 48 citations2010: 78 citations2011: 110 citations2012: 246 citations2013: 279 citations2014: 309 citations2015: 376 citations2016: 337 citations2017: 319 citations2018: 418 citations2019: 968 citations2020: 1,208 citations2021: 1,239 citations2022: 968 citations2023: 718 citations2024: 895 citations2025: 488 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,576 citing papers, 21.2% of this breakdownChina: 2,017 citing papers, 16.6% of this breakdownFrance: 976 citing papers, 8% of this breakdownGermany: 602 citing papers, 4.9% of this breakdownItaly: 566 citing papers, 4.7% of this breakdownUnited Kingdom: 543 citing papers, 4.5% of this breakdownJapan: 399 citing papers, 3.3% of this breakdownCanada: 324 citing papers, 2.7% of this breakdownSpain: 274 citing papers, 2.2% of this breakdownAustralia: 264 citing papers, 2.2% of this breakdownSweden: 260 citing papers, 2.1% of this breakdownBelgium: 255 citing papers, 2.1% of this breakdown
0%21.2%Other 25.5%

Fields

  • Medicine50%
  • Immunology and Microbiology23.4%
  • Biochemistry, Genetics and Molecular Biology20.3%
  • Engineering2.2%
  • Neuroscience1.5%
  • Psychology0.5%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers13.2%
  • Immunotherapy and Immune Responses8.8%
  • Immune Cell Function and Interaction6.3%
  • CAR-T cell therapy research4%
  • Immune cells in cancer3.9%
  • T-cell and B-cell Immunology2.3%
  • Other61.5%

Coauthors

All papers

Open in search
  1. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

    Authors: , , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2015 cited by 1,158

  2. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip Rosenstiel, Didier Raoult, Vincent Cattoir, Ivo G. Boneca, Mathias Chamaillard, Laurence Zitvogel - Immunity 2016 cited by 854

  3. Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 cited by 982

  4. VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

    Authors: , , , , , , , , , - Cancer Research 2012 cited by 659

  5. Consensus guidelines for the detection of immunogenic cell death

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zong Sheng Guo, Akseli Hemminki, Martin Herrmann, James W. Hodge, Stefan Holdenrieder, Jamie Honeychurch, Hong‐Ming Hu, Xing Huang, Tim Illidge, Koji Kono, Mladen Korbelik, Dmitri V. Krysko, Sherene Loi, Pedro R. Löwenstein, Enrico Lugli, Yuting Ma, Frank Madeo, Angelo A. Manfredi, Isabelle Martins, Domenico Mavilio, Laurie Menger, Nicolò Merendino, Michael Michaud, Grégoire Mignot, Karen Mossman, Gabriele Multhoff, Rudolf Oehler, Fabio Palombo, Theocharis Panaretakis, Jonathan Pol, Enrico Proietti, Jean‐Ehrland Ricci, Chiara Riganti, Patrizia Rovere–Querini, Anna Rubartelli, Antonella Sistigu, Mark J. Smyth, Juergen Sonnemann, Radek Špíšek, John Stagg, Abdul Qader Sukkurwala, Éric Tartour, Andrew Thorburn, Stephen H. Thorne, Peter Vandenabeele, Francesca Velotti, Samuel T. Workenhe, Haining Yang, Wei‐Xing Zong, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi - OncoImmunology 2014 cited by 824

  6. Resident memory T cells, critical components in tumor immunology

    Authors: , , , , , , , - Journal for ImmunoTherapy of Cancer 2018 cited by 333

  7. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Hank, Taisuke Baba, Duc Huynh, Remco T. A. Megens, Klaus‐Peter Janssen, Martin Jastroch, Daniel Lamp, Svenja Ruehland, Mauro Di Pilato, Jasper N. Pruessmann, Moritz Thomas, Carsten Marr, Steffen Ormanns, Anna Reischer, Michael Hristov, Éric Tartour, Emmanuel Donnadieu, Simon Rothenfußer, Peter Duewell, Lars M. König, Max Schnurr, Marion Subklewe, Andrew S. Liss, Niels Halama, Maximilian Reichert, Thorsten R. Mempel, Stefan Endres, Sebastian Kobold - Nature Biomedical Engineering 2021 cited by 175

  8. Transplantation of Human Embryonic Stem Cell–Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2018 cited by 442

  9. Crizotinib-induced immunogenic cell death in non-small cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuting Ma, Mikaël J. Pittet, Oliver Kepp, Guido Kroemer - Nature Communications 2019 cited by 300

  10. Induction of resident memory T cells enhances the efficacy of cancer vaccine

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2017 cited by 296

  11. Immune infiltration in human tumors: a prognostic factor that should not be ignored

    Authors: , , , , , - Oncogene 2009 cited by 1,102

  12. Trial watch: IDO inhibitors in cancer therapy

    Authors: , , , , , , , , , - OncoImmunology 2014 cited by 325

  13. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

    Authors: , , , , , , , , , - ESMO Open 2017 cited by 324

  14. CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 cited by 87

  15. Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Research 2016 cited by 207

  16. Classification of current anticancer immunotherapies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jérôme Galon, Abhishek D. Garg, François Ghiringhelli, Giuseppe Giaccone, Eli Gilboa, Sacha Gnjatic, Axel Hoos, Anne Hosmalin, Dirk Jäger, Paweł Kaliński, Klas Kärre, Oliver Kepp, Rolf Kiessling, John M. Kirkwood, Eva Klein, Alexander Knuth, Claire E. Lewis, Roland Liblau, Michael T. Lotze, Enrico Lugli, J P Mach, Fabrizio Mattei, Domenico Mavilio, Ignacio Melero, Cornelis J.M. Melief, Elizabeth A. Mittendorf, Lorenzo Moretta, Adekunke Odunsi, Hideho Okada, A. Karolina Palucka, Marcus E. Peter, Kenneth J. Pienta, Angel Porgador, George C. Prendergast, Gabriel A. Rabinovich, Nicholas P. Restifo, Naiyer A. Rizvi, Catherine Sautès‐Fridman, Hans Schreiber, Barbara Seliger, Hiroshi Shiku, Bruno Silva‐Santos, Mark J. Smyth, Daniel E. Speiser, Radek Špíšek, Pramod K. Srivastava, James E. Talmadge, Éric Tartour, Sjoerd H. van der Burg, Benoı̂t J. Van den Eynde, Richard G. Vile, Hermann Wagner, Jeffrey S. Weber, Theresa L. Whiteside, Jedd D. Wolchok, Laurence Zitvogel, Weiping Zou, Guido Kroemer - Oncotarget 2014 cited by 470

  17. CXCR6 expressing T cells: Functions and role in the control of tumors

    Authors: , , , , , , , , , , - Frontiers in Immunology 2022 cited by 104

  18. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

    Authors: , , , , , , - Clinical Microbiology and Infection 2021 cited by 214

  19. IL-18 Induces PD-1–Dependent Immunosuppression in Cancer

    Authors: , , , , , , , , , , , , , , , , - Cancer Research 2011 cited by 357

  20. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

    Authors: , , , , , , , , , , , , , - OncoImmunology 2015 cited by 297

  21. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

    Authors: , , , , , , , , - OncoImmunology 2012 cited by 245

  22. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacques Fellay, Magnus Fontes, António A. Freitas, Odile Gelpi, Ivo Gomperts-Boneca, Serge Herçberg, Olivier Lantz, Claude Leclerc, Hugo Mouquet, Étienne Patin, Sandra Pellegrini, Stanislas Pol, Antonio Raussel, Lars Rogge, Anavaj Sakuntabhai, Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Vassili Soumelis, Frédéric Tangy, Éric Tartour, Antoine Toubert, Marie‐Noëlle Ungeheuer, Lluís Quintana‐Murci, Matthew L. Albert - National Academy of Sciences, Proceedings of the National Academy of Sciences 2017 cited by 238

  23. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report: Figure 1

    Authors: , , , , , , , , , , , , , , , , , - European Heart Journal 2015 cited by 434

  24. PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2012 cited by 634